[go: up one dir, main page]

PL3256125T3 - Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1 - Google Patents

Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1

Info

Publication number
PL3256125T3
PL3256125T3 PL15807916T PL15807916T PL3256125T3 PL 3256125 T3 PL3256125 T3 PL 3256125T3 PL 15807916 T PL15807916 T PL 15807916T PL 15807916 T PL15807916 T PL 15807916T PL 3256125 T3 PL3256125 T3 PL 3256125T3
Authority
PL
Poland
Prior art keywords
ponesimod
selective
receptor agonist
dosing regimen
regimen
Prior art date
Application number
PL15807916T
Other languages
English (en)
Inventor
Jasper Dingemanse
Matthias Hoch
Andreas Krause
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54843844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3256125(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of PL3256125T3 publication Critical patent/PL3256125T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
PL15807916T 2014-12-11 2015-12-10 Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1 PL3256125T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP2014077469 2014-12-11
EP2015058202 2015-04-15
EP15807916.0A EP3256125B1 (en) 2014-12-11 2015-12-10 Dosing regimen for ponesimod, a selective s1p1 receptor agonist
PCT/EP2015/079208 WO2016091996A1 (en) 2014-12-11 2015-12-10 Dosing regimen for a selective s1p1 receptor agonist

Publications (1)

Publication Number Publication Date
PL3256125T3 true PL3256125T3 (pl) 2022-05-09

Family

ID=54843844

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15807916T PL3256125T3 (pl) 2014-12-11 2015-12-10 Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1

Country Status (33)

Country Link
US (5) US10220023B2 (pl)
EP (2) EP4056179A1 (pl)
JP (1) JP6244497B1 (pl)
KR (4) KR20230147768A (pl)
CN (2) CN106999461A (pl)
AU (2) AU2015359346B2 (pl)
CA (1) CA2968180C (pl)
CL (1) CL2017001457A1 (pl)
CY (1) CY1125170T1 (pl)
DK (1) DK3256125T3 (pl)
EA (1) EA036075B1 (pl)
ES (1) ES2909071T3 (pl)
FR (1) FR22C1021I2 (pl)
HR (1) HRP20220359T8 (pl)
HU (2) HUE057865T2 (pl)
IL (1) IL252727B (pl)
LT (2) LT3256125T (pl)
LU (1) LUC00262I2 (pl)
MX (2) MX379273B (pl)
MY (1) MY188764A (pl)
NL (1) NL301174I2 (pl)
NO (1) NO2022023I1 (pl)
PH (1) PH12017501059A1 (pl)
PL (1) PL3256125T3 (pl)
PT (1) PT3256125T (pl)
RS (1) RS63048B1 (pl)
SG (1) SG11201704563RA (pl)
SI (1) SI3256125T1 (pl)
SM (1) SMT202200137T1 (pl)
TW (1) TW201625242A (pl)
UA (1) UA122064C2 (pl)
WO (1) WO2016091996A1 (pl)
ZA (1) ZA201704624B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0909625B1 (pt) 2008-03-17 2021-09-08 Actelion Pharmaceuticals Ltd Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
AU2015359346B2 (en) 2014-12-11 2020-05-07 Laboratoires Juvise Pharmaceuticals Dosing regimen for a selective S1P1 receptor agonist
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
CA3145269A1 (en) 2019-07-22 2021-01-28 Michel BURCKLEN Use of ponesimod for the treatment of multiple sclerosis
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
TW202146015A (zh) 2020-03-06 2021-12-16 瑞士商艾克泰聯製藥有限公司 減緩腦體積損失之方法
CN117042738A (zh) 2021-03-17 2023-11-10 埃科特莱茵药品有限公司 药物剂量系统
WO2023062511A1 (en) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
US20230113378A1 (en) 2021-10-11 2023-04-13 Actelion Pharmaceuticals Ltd Methods Of Treating Multiple Sclerosis
CA3220684A1 (en) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
CA3220723A1 (en) 2021-10-11 2023-04-20 Allitia DIBERNARDO Methods of treating multiple sclerosis
CA3220549A1 (en) 2021-11-05 2023-05-11 Allitia DIBERNARDO Methods for treating multiple sclerosis
CA3220702A1 (en) 2022-02-11 2023-08-17 Actelion Pharmaceuticals Ltd Methods of slowing an increase in brain ventricular volume

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
US7538135B2 (en) 2003-07-08 2009-05-26 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
PL1689726T3 (pl) 2003-11-21 2011-05-31 Actelion Pharmaceuticals Ltd Pochodne 5-(benz-(z)-ylideno)tiazolidyn-4-onu jako środki immunosupresyjne
WO2005082841A1 (en) 2004-02-24 2005-09-09 Irm Llc Immunosuppressant compounds and compositions
DE14172396T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
US20090275553A1 (en) 2004-11-29 2009-11-05 Kovarik John M Dosage regimen of an s1p receptor agonist
US7879821B2 (en) 2006-01-26 2011-02-01 University Of Medicine And Dentistry Of New Jersey Method for modulating inflammatory responses by altering plasma lipid levels
EP2489662B1 (en) 2006-11-23 2014-08-06 Actelion Pharmaceuticals Ltd. Intermediates of a new process for the preparation of 5-benzylidene-2-alkylimino-3-phenylthiazolidin-4-one derivatives
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
PT2137537E (pt) 2007-02-08 2013-08-22 Biogen Idec Inc Composições e respectivas utilizações para o tratamento da esclerose múltipla
BRPI0909625B1 (pt) 2008-03-17 2021-09-08 Actelion Pharmaceuticals Ltd Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
EP2370438A1 (en) 2008-12-04 2011-10-05 Exelixis, Inc. Imidazo [1,2a]pyridine derivatives, their use as s1p1 agonists and methods for their production
BRPI0923213A2 (pt) 2008-12-22 2016-01-26 Novaris Ag regime de dosagem de um agonista do receptor para s1p.
SI3409274T1 (sl) 2008-12-22 2020-03-31 Novartis Ag Režim odmerjanja za S1P receptor agonist
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
CN109044985A (zh) 2009-01-09 2018-12-21 前进制药知识产权有限公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
US20100260755A1 (en) 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
CA2782415A1 (en) 2009-12-01 2011-06-09 Metanomics Health Gmbh Means and methods for diagnosing multiple sclerosis
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
EP2455080A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
CN103732062A (zh) 2011-05-26 2014-04-16 比奥根艾迪克Ma公司 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法
EP2715361A1 (en) 2011-05-31 2014-04-09 Metanomics Health GmbH Methods for diagnosing multiple sclerosis
AU2013203445C1 (en) 2012-02-07 2017-04-20 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
US20130314669A1 (en) 2012-05-24 2013-11-28 Hadasit Medical Research Services And Development Ltd. Method and system for assessing visual disorder
NZ703851A (en) 2012-07-27 2017-01-27 Biogen Ma Inc Compounds that are s1p modulating agents and/or atx modulating agents
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
US10273234B2 (en) 2012-08-06 2019-04-30 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
US9499485B2 (en) 2012-08-06 2016-11-22 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
EP2883177A1 (en) 2012-08-13 2015-06-17 Biogen Idec MA Inc. Disease progression parameters and uses thereof for evaluating multiple sclerosis
HUE050733T2 (hu) 2012-08-17 2021-01-28 Actelion Pharmaceuticals Ltd Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
HK1213794A1 (zh) 2012-10-09 2016-07-15 Biogen Ma Inc. 联合治疗及用於治疗脱髓鞘病症的用途
WO2014071371A1 (en) 2012-11-05 2014-05-08 Xenoport, Inc. Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate
UA116648C2 (uk) 2013-03-14 2018-04-25 Алкермес Фарма Айерленд Лімітед Фумарати як проліки та їх застосування при лікуванні різних захворювань
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
EP3062792A1 (en) 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
AU2015359346B2 (en) * 2014-12-11 2020-05-07 Laboratoires Juvise Pharmaceuticals Dosing regimen for a selective S1P1 receptor agonist

Also Published As

Publication number Publication date
HRP20220359T1 (hr) 2022-05-13
HUS2200021I1 (hu) 2022-05-28
CA2968180C (en) 2020-01-28
NO2022023I1 (no) 2022-06-10
JP6244497B1 (ja) 2017-12-06
US20250281463A1 (en) 2025-09-11
HRP20220359T8 (hr) 2022-05-27
LTPA2022505I1 (pl) 2022-06-10
MX2020011182A (es) 2022-10-03
US10857134B2 (en) 2020-12-08
AU2015359346A1 (en) 2017-07-27
KR20170094335A (ko) 2017-08-17
SG11201704563RA (en) 2017-07-28
EA036075B1 (ru) 2020-09-23
EP3256125A1 (en) 2017-12-20
SI3256125T1 (sl) 2022-04-29
JP2017538706A (ja) 2017-12-28
CN117137912A (zh) 2023-12-01
ES2909071T3 (es) 2022-05-05
UA122064C2 (uk) 2020-09-10
PT3256125T (pt) 2022-05-06
LTC3256125I2 (pl) 2024-03-12
EP4056179A1 (en) 2022-09-14
AU2015359346A8 (en) 2017-08-03
WO2016091996A1 (en) 2016-06-16
US20210052555A1 (en) 2021-02-25
HUE057865T2 (hu) 2022-06-28
SMT202200137T1 (it) 2022-05-12
US10220023B2 (en) 2019-03-05
LT3256125T (lt) 2022-04-11
FR22C1021I2 (fr) 2023-04-14
US20190151292A1 (en) 2019-05-23
MX379273B (es) 2025-03-11
AU2015359346B2 (en) 2020-05-07
NZ733463A (en) 2023-10-27
CL2017001457A1 (es) 2018-02-09
DK3256125T3 (da) 2022-03-21
PH12017501059A1 (en) 2017-11-27
KR102427123B1 (ko) 2022-07-28
LUC00262I2 (pl) 2025-04-25
KR20200013086A (ko) 2020-02-05
CA2968180A1 (en) 2016-06-16
TW201625242A (zh) 2016-07-16
FR22C1021I1 (fr) 2022-07-15
MY188764A (en) 2021-12-30
ZA201704624B (en) 2022-03-30
KR20210126792A (ko) 2021-10-20
US20180147188A9 (en) 2018-05-31
US20230131600A1 (en) 2023-04-27
EA201791286A1 (ru) 2017-12-29
NL301174I1 (pl) 2022-05-09
US20170319555A1 (en) 2017-11-09
RS63048B1 (sr) 2022-04-29
US12336980B2 (en) 2025-06-24
MX2017007638A (es) 2017-09-11
KR102590068B1 (ko) 2023-10-16
CY1125170T1 (el) 2022-07-22
CN106999461A (zh) 2017-08-01
KR20230147768A (ko) 2023-10-23
EP3256125B1 (en) 2022-01-26
IL252727B (en) 2021-02-28
IL252727A0 (en) 2017-08-31
AU2020202684A1 (en) 2020-05-14
NZ768672A (en) 2023-10-27
US11771683B2 (en) 2023-10-03
NL301174I2 (nl) 2022-06-09

Similar Documents

Publication Publication Date Title
HUS2200021I1 (hu) A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
CY2022011I2 (el) Δοσολογικο σχημα για την πονεσιμοδη, εναν επιλεκτικο αγωνιστη του υποδοχεα s1p1
IL252257A0 (en) Insulin receptor partial agonists
SG11201700669RA (en) Arranging a transport service for multiple users
SG11201606502YA (en) Fgf-18 compound dosing regimen
LT3433493T (lt) Dozavimo siurblys dozavimo prietaisui, taip pat dozavimo prietaisas
GB2540877B (en) A dosing apparatus
HK1248524A1 (en) Dosing regimen for a selective s1p1 receptor agonist
GB2537080B (en) A dosing device
GB201720519D0 (en) Dosing regimen
GB201718106D0 (en) Dosing regimen
GB201718000D0 (en) Dosing regimen
GB201717694D0 (en) Dosing regimen
AU2017903935A0 (en) Metabolite inspired selective oxytocin receptor agonists
GB201609758D0 (en) Dosing Regimen
GB201501974D0 (en) Network subscription for a new device
GB201420410D0 (en) E-Liquid filling machine